GlassScriptPhysician profile
Jessica Morrow
NPI 1396217634
$4,027.78
in general payments reported to CMS, 2019-2025
21 companies · $676 in 2025
The $676 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $954 · 2022: $993 · 2023: $737 · 2024: $668 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.24 |
| Education | $310.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $629.32 | 2021-2025 | |
| Abbvie INC. | $554.64 | 2021-2025 | |
| Astellas Pharma US INC | $491.44 | 2022-2025 | Veozah |
| Sumitomo Pharma America, INC. | $341.11 | 2023-2025 | Myfembree |
| Pfizer INC. | $303.37 | 2021-2024 | |
| Exeltis, USA INC. | $259.35 | 2021-2023 | Slynd |
| Myovant Sciences INC. | $195.97 | 2021-2022 | |
| Aspira Women'S Health INC | $158.27 | 2021 | |
| Biogen, INC. | $156.52 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $150.67 | 2021-2025 | Aptima, Thinprep 2000 Processor, Fluent Fluid Management System |
| Bayer Healthcare Pharmaceuticals INC. | $143.43 | 2021-2025 | |
| Organon LLC | $127.06 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $125.00 | 2021-2022 | |
| Shield Therapeutics INC | $87.78 | 2023-2024 | Accrufer |
| Urovant Sciences INC | $75.40 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $61.19 | 2021-2022 | |
| Avion Pharmaceuticals | $58.56 | 2021-2022 | |
| Minerva Surgical, INC | $48.70 | 2025 | |
| Millicent US INC | $26.70 | 2024 | |
| Evofem Biosciences, INC. | $19.21 | 2022 | |
| Currax Pharmaceuticals LLC | $14.09 | 2024 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.